ELIZABETH HEAD

Dr. ELIZABETH HEAD

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2007 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
RKRakez Kayed
Rakez Kayed
EHELIZABETH HEAD
ELIZABETH HEAD
FSFloyd Sarsoza
Floyd Sarsoza
TSTommy Saing
Tommy Saing
CCCarl W Cotman
Carl W Cotman
CGCharles G Glabe
Charles G Glabe
Background: Amyloid-related degenerative diseases are associated with the accumulation of misfolded proteins as amyloid fibrils in tissue. In Alzheimer disease (AD), amyloid accumulates in several distinct types of insoluble plaque deposits, intracellular Aβ and as soluble oligomers and the relationships between these deposits and their pathological significance remains unclear. Conformation dependent antibodies have been reported that specifically recognize distinct assembly states of amyloids, including prefibrillar oligomers and fibrils. Results: We immunized rabbits with a morphologically homogeneous population of Aβ42 fibrils. The resulting immune serum (OC) specifically recognizes fibrils, but not random coil monomer or prefibrillar oligomers, indicating fibrils display a distinct conformation dependent epitope that is absent in prefibrillar oligomers. The fibril epitope is also displayed by fibrils of other types of amyloids, indicating that the epitope is a generic feature of the polypeptide backbone. The fibril specific antibody also recognizes 100,000 × G soluble fibrillar oligomers ranging in size from dimer to greater than 250 kDa on western blots. The fibrillar oligomers recognized by OC are immunologically distinct from prefibrillar oligomers recognized by A11, even though their sizes overlap broadly, indicating that size is not a reliable indicator of oligomer conformation. The immune response to prefibrillar oligomers and fibrils is not sequence specific and antisera of the same specificity are produced in response to immunization with islet amyloid polypeptide prefibrillar oligomer mimics and fibrils. The fibril specific antibodies stain all types of amyloid deposits in human AD brain. Diffuse amyloid deposits stain intensely with anti-fibril antibody although they are thioflavin S negative, suggesting that they are indeed fibrillar in conformation. OC also stains islet amyloid deposits in transgenic mouse models of type II diabetes, demonstrating its generic specificity for amyloid fibrils. Conclusion: Since the fibril specific antibodies are conformation dependent, sequence-independent, and recognize epitopes that are distinct from those present in prefibrillar oligomers, they may have broad utility for detecting and characterizing the accumulation of amyloid fibrils and fibrillar type oligomers in degenerative diseases.

14 June 2022 in Cell Reports
Verified
Journal Article
Open access
SSSepideh Kiani Shabestari
Sepideh Kiani Shabestari
SMSamuel Morabito
Samuel Morabito
EDEmma Pascal Danhash
Emma Pascal Danhash
AMAmanda McQuade
Amanda McQuade
JSJessica Ramirez Sanchez
Jessica Ramirez Sanchez
MBMathew Blurton-Jones
Mathew Blurton-Jones
Microglia are strongly implicated in the development and progression of Alzheimer’s disease (AD), yet their impact on pathology and lifespan remains unclear. Here we utilize a CSF1R hypomorphic mouse to generate a model of AD that genetically lacks microglia. The resulting microglial-deficient mice exhibit a profound shift from parenchymal amyloid plaques to cerebral amyloid angiopathy (CAA), which is accompanied by numerous transcriptional changes, greatly increased brain calcification and hemorrhages, and premature lethality. Remarkably, a single injection of wild-type microglia into adult mice repopulates the microglial niche and prevents each of these pathological changes. Taken together, these results indicate the protective functions of microglia in reducing CAA, blood-brain barrier dysfunction, and brain calcification. To further understand the clinical implications of these findings, human AD tissue and iPSC-microglia were examined, providing evidence that microglia phagocytose calcium crystals, and this process is impaired by loss of the AD risk gene, TREM2.

3 July 2002 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
EHELIZABETH HEAD
ELIZABETH HEAD
JLJ. Liu
J. Liu
THT. M. Hagen
T. M. Hagen
BMB. A. Muggenburg
B. A. Muggenburg
NMN. W. Milgram
N. W. Milgram
CCC. W. Cotman
C. W. Cotman
We assayed levels of lipid peroxidation, protein carbonyl formation, glutamine synthetase (GS) activity and both oxidized and reduced glutathione to study the link between oxidative damage, aging and β‐amyloid (Aβ) in the canine brain. The aged canine brain, a model of human brain aging, naturally develops extensive diffuse deposits of human‐type Aβ. Aβ was measured in immunostained prefrontal cortex from 19 beagle dogs (4–15 years). Increased malondialdehyde (MDA), which indicates increased lipid peroxidation, was observed in the prefrontal cortex and serum but not in cerebrospinal fluid (CSF). Oxidative damage to proteins (carbonyl formation) also increased in brain. An age‐dependent decline in GS activity, an enzyme vulnerable to oxidative damage, and in the level of glutathione (GSH) was observed in the prefrontal cortex. MDA level in serum correlated with MDA accumulation in the prefrontal cortex. Although 11/19 animals exhibited Aβ, the extent of deposition did not correlate with any of the oxidative damage measures, suggesting that each form of neuropathology accumulates in parallel with age. This evidence of widespread oxidative damage and Aβ deposition is further justification for using the canine model for studying human brain aging and neurodegenerative diseases.

17 December 2008 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
CCCarl W Cotman
Carl W Cotman
EHELIZABETH HEAD
ELIZABETH HEAD
Aged dogs (beagles) develop losses in executive function, learning and memory. The severity of decline in these cognitive domains represents a spectrum that captures normal aging, mild cognitive impairment and early/mild Alzheimer's disease (AD) in h

1 September 1998 in Neurobiology of Aging
Verified
Journal Article
Closed access
EHELIZABETH HEAD
ELIZABETH HEAD
HCH. Callahan
H. Callahan
BMB.A. Muggenburg
B.A. Muggenburg
CCC.W. Cotman
C.W. Cotman
NMN.W. Milgram
N.W. Milgram

1 January 2000 in Neurobiology of Aging
Verified
Journal Article
Closed access
EHELIZABETH HEAD
ELIZABETH HEAD
RMR McCleary
R McCleary
FHF.F Hahn
F.F Hahn
NMN.W Milgram
N.W Milgram
CCC.W Cotman
C.W Cotman